New drug combo targets tough cancers in early trial

NCT ID NCT04130542

Completed Disease control Sponsor: Lyvgen Biopharma Holdings Limited Source: ClinicalTrials.gov ↗

First seen May 23, 2026 · Last updated May 23, 2026

Summary

This early-phase study tested a new drug called LVGN6051, given alone or with the immunotherapy Keytruda, in 105 adults with advanced or spreading cancers. The main goal was to find safe doses and check for side effects. The study is complete, but results are not yet available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

MD Anderson Cancer Center

Houston, Texas, 77030-3722, United States
NYU Langone Health

New York, New York, 10016, United States
Nebraska Cancer Specialist

Omaha, Nebraska, 68130, United States
The Johns Hopkins University

Baltimore, Maryland, 21205, United States
UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94115, United States
University of California Irvine Health

Orange, California, 92868, United States
Verdi Oncology Research

Lafayette, Indiana, 47905, United States

Conditions

Explore the condition pages connected to this study.

CANCER